Cargando…

CCN5/WISP-2 restores ER-∝ in normal and neoplastic breast cells and sensitizes triple negative breast cancer cells to tamoxifen

CCN5/WISP-2 is an anti-invasive molecule and prevents breast cancer (BC) progression. However, it is not well understood how CCN5 prevents invasive phenotypes of BC cells. CCN5 protein expression is detected in estrogen receptor-α (ER-α) -positive normal breast epithelial cells as well as BC cells,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sarkar, S, Ghosh, A, Banerjee, S, Maity, G, Das, A, Larson, M A, Gupta, V, Haque, I, Tawfik, O, Banerjee, S K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569333/ https://www.ncbi.nlm.nih.gov/pubmed/28530705 http://dx.doi.org/10.1038/oncsis.2017.43

Ejemplares similares

Deficiency of CCN5/WISP-2-Driven Program in breast cancer Promotes Cancer Epithelial cells to mesenchymal stem cells and Breast Cancer growth
por: Das, Amlan, et al.
Publicado: (2017)

Inhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells
por: Zhang, Yanhong, et al.
Publicado: (2005)

CCN5/WISP2 and metabolic diseases
por: Grünberg, John R, et al.
Publicado: (2017)

The role of CCN4/WISP-1 in the cancerous phenotype
por: Nivison, Mary P, et al.
Publicado: (2018)

Leptin-induced ER-α-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway
por: Haque, Inamul, et al.
Publicado: (2018)

The matricellular protein CCN6 (WISP3) decreases Notch1 and suppresses breast cancer initiating cells
por: Huang, Wei, et al.
Publicado: (2016)

Pancreatic Tumor Cell Secreted CCN1/Cyr61 Promotes Endothelial cell migration and Aberrant Neovascularization
por: Maity, Gargi, et al.
Publicado: (2014)

CCN5 activation by free or encapsulated EGCG is required to render triple‐negative breast cancer cell viability and tumor progression
por: Das, Amlan, et al.
Publicado: (2021)

WISP2/CCN5 Suppresses Vasculogenic Mimicry through Inhibition of YAP/TAZ Signaling in Breast Cancer Cells
por: Ferrand, Nathalie, et al.
Publicado: (2022)

Prospects and Perspectives for WISP1 (CCN4) in Diabetes Mellitus
por: Maiese, Kenneth
Publicado: (2020)

CYR61/CCN1 and WISP3/CCN6 are chemoattractive ligands for human multipotent mesenchymal stroma cells
por: Schütze, Norbert, et al.
Publicado: (2007)

WISP-1/CCN4 Regulates Osteogenesis by Enhancing BMP-2 Activity
por: Ono, Mitsuaki, et al.
Publicado: (2011)

An Update to the WISP-1/CCN4 Role in Obesity, Insulin Resistance and Diabetes
por: Mirr, Małgorzata, et al.
Publicado: (2021)

CCN4/WISP1 Promotes Migration of Human Primary Osteoarthritic Chondrocytes
por: Timmermans, Ritchie G.M., et al.
Publicado: (2022)

Loss of WISP2/CCN5 in Estrogen-Dependent MCF7 Human Breast Cancer Cells Promotes a Stem-Like Cell Phenotype
por: Ferrand, Nathalie, et al.
Publicado: (2014)

Normal growth and development in mice over-expressing the CCN family member WISP3
por: Nakamura, Yukio, et al.
Publicado: (2009)

Metabolic Effects of CCN5/WISP2 Gene Deficiency and Transgenic Overexpression in Mice
por: Alami, Tara, et al.
Publicado: (2021)

Disruption of the ER-α36-EGFR/HER2 Positive Regulatory Loops Restores Tamoxifen Sensitivity in Tamoxifen Resistance Breast Cancer Cells
por: Yin, Li, et al.
Publicado: (2014)

Tamoxifen Action in ER-Negative Breast Cancer
por: Manna, Subrata, et al.
Publicado: (2016)

WISP1/CCN4 inhibits adipocyte differentiation through repression of PPARγ activity
por: Ferrand, Nathalie, et al.
Publicado: (2017)

Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ
por: Mishra, Ameet K., et al.
Publicado: (2016)

miR-221/222 sponge abrogates tamoxifen resistance in ER-positive breast cancer cells through restoring the expression of ERα
por: Ouyang, Yan Xiu, et al.
Publicado: (2021)

WISP1/CCN4: A Potential Target for Inhibiting Prostate Cancer Growth and Spread to Bone
por: Ono, Mitsuaki, et al.
Publicado: (2013)

Picking a bone with WISP1 (CCN4): new strategies against degenerative joint disease
por: Maiese, Kenneth
Publicado: (2016)

Association of WISP1/CCN4 with Risk of Overweight and Gestational Diabetes Mellitus in Chinese Pregnant Women
por: Liu, Lei, et al.
Publicado: (2020)

Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer
por: Zboril, Emily K., et al.
Publicado: (2023)

Epigenetic restoration and activation of ERβ: an inspiring approach for treatment of triple-negative breast cancer
por: Salahuddin, Ahmad, et al.
Publicado: (2022)

MIND model for triple-negative breast cancer in syngeneic mice for quick and sequential progression analysis of lung metastasis
por: Ghosh, Arnab, et al.
Publicado: (2018)

Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
por: Esserman, Laura J, et al.
Publicado: (2005)

Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53
por: Scarpetti, Lauren, et al.
Publicado: (2023)

WISP-1, a novel angiogenic regulator of the CCN family, promotes oral squamous cell carcinoma angiogenesis through VEGF-A expression
por: Chuang, Jing-Yuan, et al.
Publicado: (2015)

Huaier extract synergizes with tamoxifen to induce autophagy and apoptosis in ER-positive breast cancer cells
por: Qi, Wenwen, et al.
Publicado: (2016)

Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells
por: Traboulsi, Tatiana, et al.
Publicado: (2018)

Enhancement of Sensitivity to Tamoxifen by Berberine in Breast Cancer Cells by Inhibiting ER-α36 Expression
por: Pan, Xiaohua, et al.
Publicado: (2022)

SAT045 Sexually Dimorphic Effects Of CCN5/WISP2 Overexpression On HFD-STZ Induced Diabetes And Glucose Intolerance
por: Alami, Tara, et al.
Publicado: (2023)

Z-ligustilide restores tamoxifen sensitivity of ERα negative breast cancer cells by reversing MTA1/IFI16/HDACs complex mediated epigenetic repression of ERα
por: Ma, Hui, et al.
Publicado: (2017)

Modulation of transforming growth factor beta expression and induction of apoptosis by tamoxifen in ER positive and ER negative breast cancer cells.
por: Benson, J. R., et al.
Publicado: (1996)

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer
por: Menendez, Javier A., et al.
Publicado: (2021)

CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance
por: Gao, Tian, et al.
Publicado: (2014)

Effects of Jaeumkanghwa-tang on tamoxifen responsiveness in preclinical ER+ breast cancer model
por: De Oliveira Andrade, Fabia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ff3s3n0qe8fkdki96b1aj1g8fv